The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine

• Bo Wang,

  Affiliations Department of Medicine, Stanford University School of Medicine, Stanford, California, United States of America, Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

  http://orcid.org/0000-0002-0354-4586

  ⨯
• David M. Studdert,

  Affiliation Center for Health Policy/Center for Primary Care and Outcomes Research Stanford Medical School & Stanford Law School, Stanford University, Stanford, California, United States of America

  ⨯
• Ameet Sarpatwari,

  Affiliation Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Jessica M. Franklin,

  Affiliation Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Joan Landon,

  Affiliation Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Aaron S. Kesselheim

  * E-mail: akesselheim@partners.org

  Affiliation Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯